Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice
SARS-CoV-2 continues to circulate in the human population necessitating regular booster immunization for its long-term control. Ideally, vaccines should ideally not only protect against symptomatic disease, but also prevent transmission via asymptomatic shedding and cover existing and future variant...
Na minha lista:
Principais autores: | , , , , , , , , , , , , , |
---|---|
Formato: | Artigo |
Idioma: | inglês |
Publicado em: |
Philipps-Universität Marburg
2023
|
Assuntos: | |
Acesso em linha: | Texto Completo em Formato PDF |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|
No abstracts were found for this record.